This Week in Respiratory Health: Breakthroughs in IPF, CF, COPD, MDR-TB, and More
From stem cell therapies for COPD to AI-powered diagnostics and major regulatory milestones, this week’s Respiratory Health Updates brings you the most critical developments transforming pulmonary care.
🧪 Key highlights:
🌬️ Savara’s molgramostim delivers statistically significant lung function improvements in aPAP—set for publication in NEJM
🧬 SMSbiotech kicks off the first-ever nebulized stem cell trial for COPD in Australia
💊 PureTech spins out Celea as deupirfenidone enters Phase 3 for IPF, outperforming pirfenidone by preserving lung function 50 percent better
🧩 Sionna starts first clinical trial targeting NBD1 stabilization in cystic fibrosis
🌿 Calluna’s CAL101 enters Phase 2 for IPF, targeting both inflammation and fibrosis
🛡️ BioVersys gains EMA orphan drug designation for its MDR-TB combination therapy with 10-year EU market exclusivity
🚀 Cereno’s CS1 wins FDA Fast Track status for PAH with promising vascular remodeling potential
🤝 MannKind expands its Technosphere®-based collaboration with United Therapeutics
🤖 Diag-Nose.io and Human Health secure $3M to develop AI-driven RhinoMAP for asthma and COPD optimization
🚨 Whether you’re tracking clinical innovation, regulatory progress, or digital health trends in pulmonary medicine, this roundup is your go-to source.
📢 Stay Ahead in Respiratory Research!
✅ Like, share, and subscribe for weekly updates on the latest respiratory breakthroughs.
#RespiratoryHealth #PulmonaryResearch #COPD #CysticFibrosis #IdiopathicPulmonaryFibrosis #RareDiseases #DrugDevelopment #StemCells #OrphanDrugs #LucidQuest #LQVentures #AIinHealthcare #ClinicalTrials #RespiratoryDiagnostics #PulmonaryHypertension #MedicalBreakthroughs